Skip to main content
SpringerLink
Log in

Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism

  • Original Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Purpose

Since its registration in 2004, the calcimimetic agent cinacalcet has been established as an alternative treatment for secondary hyperparathyroidism (SHPT). Working by allosteric activation of the calcium-sensing receptor, cinacalcet can lower parathyroid hormone (PTH) and calcium (Ca) in patients with SHPT. The influence of calcimimetics on the perioperative course has been unclear so far.

Methods

We retrospectively analyzed the data of patients with primary operation for SHPT between 2004 and 2011, comparing the perioperative course of patients with and without preoperative cinacalcet treatment.

Results

Fifty-six patients had cinacalcet therapy, and 54 patients had no calcimimetic medication prior to surgery. Gender, age, hemodialysis, and medical treatment were similar in both groups. Also, PTH levels were similar preoperatively and postoperatively (preoperative, 1,249 ± 676 vs. 1,196 ± 601 pg/ml; postoperative, 86 ± 220 vs. 62 ± 91 pg/ml). Patients with cinacalcet preoperatively had significant lower Ca levels preoperatively (2.49 ± 0.25 vs. 2.61 ± 0.24 mmol/l) and postoperatively (1.75 ± 0.37 vs. 1.86 ± 0.35 mmol/l) and had a higher rate of oral Ca substitution postoperatively (93 vs. 74 %). The risk for postoperative persistent disease was slightly higher in these patients compared to those without preoperative cinacalcet therapy (5 vs. 0 %, not significant).

Conclusions

In our experience, cinacalcet did not alter the perioperative course in SHPT patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Messa P, Alfieri C, Brezzi B (2008) Cinacalcet: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol 4:1551–1560. doi:10.1517/17425250802587017

    Article  PubMed  CAS  Google Scholar 

  2. Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525

    Article  PubMed  CAS  Google Scholar 

  3. Bover J, Pérez R, Molina M, Benavides B, Ariza F, Miguel JL, Tornero F, Torregrosa JV (2010) Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice. Nephron Clin Pract 118:c109–c121. doi:10.1159/000319882

    Article  PubMed  Google Scholar 

  4. de Francisco ALM (2008) New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opin Pharmacother 9:795–811. doi:10.1517/14656566.9.5.795

    Article  PubMed  Google Scholar 

  5. Dotzenrath C (2010) Indications for parathyroidectomy in renal hyperparathyroidism. Comments on the significance of new therapeutics. Chirurg 81:902–908. doi:10.1007/s00104-010-1968-5

    Article  PubMed  CAS  Google Scholar 

  6. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A (2012) Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. Int Urol Nephrol 44:541–547. doi:10.1007/s11255-010-9897-2

    Article  PubMed  CAS  Google Scholar 

  7. Smith DH, Johnson ES, Thorp ML, Yang X, Neil N (2009) Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcome. J Bone Miner Metab 27:287–294. doi:10.1007/s00774-009-0048-8

    Article  PubMed  Google Scholar 

  8. Strippoli GFM, Tong A, Palmer SC, Elder GJ, Craig JC (2006) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 18:CD006254. doi:10.1002/14651858.CD006254

    Google Scholar 

  9. Costa-Hong V, Jorgetti V, Gowdak LHW, Moyses RMA, Krieger EM, De Lima JJG (2007) Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 142:699–703. doi:10.1016/j.surg.2007.06.015

    Article  PubMed  Google Scholar 

  10. Elder GJ (2005) Parathyroidectomy in the calcimimetic era. Nephrology (Carlton) 10:511–515. doi:10.1111/j.1440-1797.2005.00476.x

    Article  CAS  Google Scholar 

  11. Lorenz K, Sekulla C, Dralle H (2011) Surgical management of renal hyperparathyroidism. Zentralbl Chir. doi:10.1055/s-0030-1262542

  12. Schlosser K, Schmitt CP, Bartholomaeus JE, Suchan KL, Buchler MW, Rothmund M, Weber T (2008) Parathyroidectomy for renal hyperparathyroidism in children and adolescents. World J Surg 32:801–806. doi:10.1007/s00268-007-9318-6

    Article  PubMed  Google Scholar 

  13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int 113:S1–S130. doi:10.1038/ki.2009.188(-197)

    Google Scholar 

  14. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1–S201. doi:10.1016/S0272-6386(03)00905-3

    Google Scholar 

  15. Amgen Inc. (2004–2011) Sensipar® (cinacalcet) tablets. Full prescribing information. Available at http://pi.amgen.com/united_states/sensipar/sensipar_pi_hcp_english.pdf. Accessed 31 Oct 2011

  16. Reichel H, Braun J (2011) German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY). Dtsch Med Wochenschr 136:123–128. doi:10.1055/s-0030-1247876

    Article  PubMed  CAS  Google Scholar 

  17. Messa P, Alfieri C, Brezzi B (2011) Clinical utilization of cinacalcet in hypercalcemic conditions. Expert Opin Drug Metab Toxicol 7:517–528. doi:10.1517/17425255.2011.562196

    Article  PubMed  CAS  Google Scholar 

  18. Frazão JM, Messa P, Mellotte GJ, Geiger H, Hagen EC, Quarles LD, Kerr PG, Baños A, Dehmel B, Urena P (2011) Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clin Nephrol 76:233–243. doi:10.5414/CN106965

    PubMed  Google Scholar 

  19. Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S, Rix M, Os I, Sha H, Ryba M, Bencova V, Baños A, Zani V, Fouque D (2009) Cinacalcet and achievement of the NKF/K-DOQI™ recommended target values for bone and mineral metabolism in real-world clinical practice—the ECHO observational study. Nephrol Dial Transplant 24:2852–2859. doi:10.1093/ndt/gfp144

    Article  PubMed  Google Scholar 

  20. Dillon ML, Frazee LA (2011) Cinacalcet for the treatment of primary hyperparathyroidism. Am J Ther 18:313–322. doi:10.1097/MJT.0b013e3181bdc3d0

    Article  PubMed  Google Scholar 

  21. Duntas LH, Stathatos N (2011) Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Endocrine 39:199–204. doi:10.1007/s12020-011-9452-7

    Article  PubMed  CAS  Google Scholar 

  22. Khan A, Grey A, Shoback D (2009) Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:373–381. doi:10.1210/jc.2008-1762

    Article  PubMed  CAS  Google Scholar 

  23. Sajid-Crockett S, Singer FR, Hershman JM (2008) Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 57:517–521. doi:10.1016/j.metabol.2007.11.014

    Article  PubMed  CAS  Google Scholar 

  24. Wüthrich RP, Martin D, Bilezikian JP (2007) The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 37:915–922. doi:10.1111/j.1365-2362.2007.01874.x

    Article  PubMed  Google Scholar 

  25. Moyes VJ, Monson JP, Chew SL, Akker SA (2010) Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol. doi:10.1155/2010/906163

  26. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800. doi:10.1111/j.1523-1755.2005.00596.x

    Article  PubMed  CAS  Google Scholar 

  27. Taniguchi M, Yamada S, Tokumoto M, Tsuruya K, Hirakata H, Fujimi S, Iida M (2009) Does cinacalcet improve the prognosis of dialysis patients? Ther Apher Dial 13(Suppl 1):S15–S19. doi:10.1111/j.1744-9987.2009.00770.x

    Article  PubMed  CAS  Google Scholar 

  28. Schlosser K, Zielke A, Rothmund M (2004) Medical and surgical treatment for secondary and tertiary hyperparathyroidism. Scand J Surg 93:288–297

    PubMed  CAS  Google Scholar 

  29. Schneider R, Bartsch DK, Schlosser K (2011) Hat sich das preoperative Erscheinungsbild vor Parathyreoidektomien bei Patienten mit sekundärem Hyperparathyreoidismus im Zeitverlauf und durch neue medikamentöse Therapieoptionen verändert? Abstract, 128th Congress of the German Society of Surgery 2011, Munich, Germany

  30. Meyers MO, Russell CP, Ollila DW, Yeh JJ, Kim HJ, Calvo BF (2009) Postoperative hypocalcemia after parathyroidectomy for renal hyperparathyroidism in the era of cinacalcet. Am Surg 75:843–847

    PubMed  Google Scholar 

  31. Ghani A, Baxter P (2011) Surgical parathyroidectomy versus cinacalcet therapy: in the management of secondary hyperparathyroidism. Otolaryngol Head Neck Surg. doi:10.1177/0194599811428272

  32. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20:2186–2193. doi:10.1093/ndt/gfh966

    Article  PubMed  CAS  Google Scholar 

  33. Hirai T, Nakashima A, Takasugi N, Yorioka N (2010) Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial 14:577–582. doi:10.1111/j.1744-9987.2010.00843.x

    Article  PubMed  CAS  Google Scholar 

  34. Hirai T, Nakashima A, Takasugi N, Yorioka N (2010) Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size. Nephron Clin Pract 114:c187–c193. doi:10.1159/000262301

    Article  PubMed  Google Scholar 

  35. Tominaga Y, Matsuoka S, Uno N, Sato T (2008) Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 12(Suppl 1):S21–S26. doi:10.1111/j.1744-9987.2008.00627.x

    Article  PubMed  Google Scholar 

  36. Miller G, Davis J, Shatzen E, Colloton M, Martin D, Henley CM (2012) Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD. Nephrol Dial Transplant 27:2198–2205. doi:10.1093/ndt/gfr589

    Article  PubMed  CAS  Google Scholar 

  37. Kakuta T, Tanaka R, Kanai G, Sawaya A, Hirukawa T, Sato A, Saito A (2009) Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism? Ther Apher Dial 13(1):S20–S27. doi:10.1111/j.1744-9987.2009.00772.x

    Article  PubMed  CAS  Google Scholar 

  38. Narayan R, Perkins RM, Berbano EP, Yuan CM, Neff RT, Sawyers ES, Yeo FE, Vidal-Trecan GM, Abbott KC (2007) Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 49:801–813. doi:10.1053/j.ajkd.2007.03.009

    Article  PubMed  Google Scholar 

  39. Schneider R, Kolios G, Koch BM, Fernández ED, Bartsch DK, Schlosser K (2010) An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism—the German perspective. Surgery 148:1091–1099. doi:10.1016/j.surg.2010.09.009

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Visceral and Endocrine Surgery, Lukaskrankenhaus Neuss, Preussenstr. 84, 41464, Neuss, Germany

    Denis Wirowski, Peter E. Goretzki, Katharina Schwarz & Bernhard J. Lammers

Authors
  1. Denis Wirowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter E. Goretzki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katharina Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernhard J. Lammers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Denis Wirowski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirowski, D., Goretzki, P.E., Schwarz, K. et al. Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism. Langenbecks Arch Surg 398, 131–138 (2013). https://doi.org/10.1007/s00423-012-1005-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-012-1005-x

Keywords

Search

Navigation